Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Sissung Website

Tristan Sissung, Ph.D., M.S.

Selected Publications

1)  Goldspiel BR, Flegel WA, Dipatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, Lertora JJ, McKeeby JW.
Integrating pharmacogenetic information and clinical decision support into the electronic health record.
J Am Med Inform Assoc. 21: 522-8, 2014.
2)  Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?.
BMJ Open. 3, 2013.
3)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
4)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
5)  Sissung TM, Reece KM, Spencer S, Figg WD.
Contribution of the OATP1B subfamily to cancer biology and treatment.
Clin. Pharmacol. Ther. 92: 658-60, 2012.
6)  Pratt E, Sissung TM, Figg WD.
Loss of OATP1B3 function causes Rotor syndrome: Implications for potential use of inhibitors in cancer.
Cancer Biol. Ther. 13, 2012.
7)  Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
Oncologist. 17: 312-20, 2012.
8)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
9)  Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Discov Med. 13: 19-34, 2012.
10)  Peer CJ, Sissung TM, Figg WD.
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.
Cancer Biol. Ther. 11: 549-51, 2011.
11)  Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD.
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
J. Clin. Endocrinol. Metab. 96: E368-72, 2011.
12)  Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.
Expression of OATP family members in hormone-related cancers: potential markers of progression.
PLoS ONE. 6: e20372, 2011.
13)  Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clin. Cancer Res. 17: 937-46, 2011.
14)  Sissung TM, Pressler H, Price DK, Figg WD.
SLCO transport genes in prostate cancer--letter.
Cancer Epidemiol. Biomarkers Prev. 20: 2325; author reply 2326-7, 2011.
15)  Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD.
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.
Mutat. Res. 708: 21-7, 2011.
16)  Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J. 10: 191-9, 2010.
17)  English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
Ther Clin Risk Manag. 6: 579-83, 2010.
18)  Sissung TM, English BC, Venzon D, Figg WD, Deeken JF.
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics. 11: 89-103, 2010.
19)  Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
BMC Cancer. 10: 511, 2010.
20)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
21)  Smith NF, Mani S, Schuetz EG, Yasuda K, Sissung TM, Bates SE, Figg WD, Sparreboom A.
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
Ann Pharmacother. 44: 1709-17, 2010.
22)  Ajiboye S, Sissung TM, Sharifi N, Figg WD.
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
BJU Int. 105: 913-6, 2010.
23)  Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD.
Pharmacogenetics of membrane transporters: an update on current approaches.
Mol. Biotechnol. 44: 152-67, 2010.
24)  Sharma H, Sissung TM, Pressler H, Figg WD.
Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.
Cancer Biol. Ther. 9: 163-5, 2010.
25)  Sissung T, Figg W.
Figg W, eds.
Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer. In: Drug Management of Prostate Cancer.
Humana Press; 2009. In Press. [Book Chapter]
26)  Jonsson JG, Sissung TM, Figg WD.
A genomic strategy for predicting androgen receptor activity in prostate tumors.
Cancer Biol. Ther. 8: 2002-3, 2009.
27)  Sissung TM, Thordardottir S, Gardner ER, Figg WD.
Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Anticancer Agents Med Chem. 9: 1058-69, 2009.
28)  Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clin. Cancer Res. 15: 1496-503, 2009.
29)  Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Mol. Cancer Ther. 8: 2496-508, 2009.
30)  Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 102: 617-21, 2008.
31)  Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD.
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clin. Cancer Res. 14: 4543-9, 2008.
32)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 102: 1694-9, 2008.
33)  Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Mol. Cancer Ther. 7: 19-26, 2008.
34)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
35)  Gao R, Price DK, Sissung T, Reed E, Figg WD.
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Mol. Cancer Ther. 7: 1246-50, 2008.
36)  Danish M, Sissung T, Price DK, Figg WD.
Genetic stability of tumor microenvironment.
Cancer Biol. Ther. 7: 331-2, 2008.
37)  Sissung TM, Gardner ER, Gao R, Figg WD.
Pharmacogenetics of membrane transporters: a review of current approaches.
Methods Mol. Biol. 448: 41-62, 2008.
38)  Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD.
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology. 70: 217-20, 2007.
39)  Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Journal of pharmaceutical sciences. 96: 2224-31, 2007.
40)  Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU Int. 99: 1047-55, 2007.
41)  Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S.
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Eur. J. Cancer. 42: 2893-6, 2006.
42)  Sissung TM, Price DK, Sparreboom A, Figg WD.
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Mol. Cancer Res. 4: 135-50, 2006.
43)  Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H.
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer Biol. Ther. 4: 650-8, 2005.
44)  Poutsma JC, Andriole EJ, Sissung T, Morton TH.
cis-1,5-Diaminocyclooctane: the most basic gaseous primary amine?.
Chem. Commun. (Camb.). 2040-1, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/15/2014.